HIMS is an exciting new company taking the awkward discomfort out of sensitive medical issues for men and women.
They have two sites – Hims and Hers.
The sites are catered to each gender and offer hair loss medications, prescription skin cream, anxiety drugs, and sexual dysfunction treatments via quick, online doctor visits. The company then ships the drugs or product directly to the customer’s home.
The company went public three years ago, and it has been a roller coaster ride for investors.
Shares have been as high as 25 and as low as
3
, all in just the last couple years.
But the stock is showing signs of a new breakout higher.
The 10, 21, and 50-day moving averages are stacked tightly below the stock to form a launchpad setup. We have also seen price consolidate nicely over the last six weeks as investors digest the blowout earnings numbers.
I bought some on Thursday near
10
per share and we issued this as a new trade idea on Friday, 4/14 just before the breakout. So far it is playing out well with a clean move on high volume.
The stock needs to stay above $9.35, or I will consider getting out.
They have two sites – Hims and Hers.
The sites are catered to each gender and offer hair loss medications, prescription skin cream, anxiety drugs, and sexual dysfunction treatments via quick, online doctor visits. The company then ships the drugs or product directly to the customer’s home.
The company went public three years ago, and it has been a roller coaster ride for investors.
Shares have been as high as 25 and as low as
3
, all in just the last couple years. But the stock is showing signs of a new breakout higher.
The 10, 21, and 50-day moving averages are stacked tightly below the stock to form a launchpad setup. We have also seen price consolidate nicely over the last six weeks as investors digest the blowout earnings numbers.
I bought some on Thursday near
10
per share and we issued this as a new trade idea on Friday, 4/14 just before the breakout. So far it is playing out well with a clean move on high volume. The stock needs to stay above $9.35, or I will consider getting out.